Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases

2Citations
Citations of this article
14Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Purpose: To (1) examine the occurrence and concentrations of aPS/PT and aPL in inflammatory bowel disease (IBD) patients at the beginning of and during anti-TNF-alpha therapy with infliximab; (2) investigate the link of the aPS/PT and aPL presence with antibodies to infliximab (ATI) formation; and (3) examine possible clinical consequences of aPS/PT and/or aPL positivity in IBD patients. Materials and methods: Thirty (30) IBD patients treated with infliximab were analyzed regarding aPS/PT, aPL, and ATI antibody serum levels by standardized ELISAs at treatment weeks 2 (W2) and 14 (W14). Results: At W2, 40 % of infliximab-treated patients had elevated aPS/PT and 16. 7 % had elevated aPL serum levels. At W14, the proportion of aPS/PT-positive sera decreased to 16. 6 %, whereas aPL distribution remained unchanged. Moreover, concentrations of aPS/PT have shown significant differences at W2 (16. 64 [10. 06; 33. 06] U for IgG and 18. 46 [9. 18; 32. 48] U for IgM) and at W14 (8. 24 [2. 78; 19. 82] U for IgG and 8. 57 [5. 55; 26. 82] U for IgM), p = 0. 009 and p = 0. 003, respectively. In ATI-positive samples, aPS/PT IgG were more frequent (p = 0. 001 for W2 and p = 0. 003 for W14), whereas aPS/PT IgM and aPL IgG/IgM did not show such association. Conclusions: Higher concentrations of aPS/PT IgG and IgM were found in IBD patients at the beginning of the biological treatment period compared to the maintenance treatment period. Moreover, aPS/PT IgG were more frequent in ATI-positive individuals, which was not observed in aPL. We speculate that there is a relationship between the aPS/PT and the severity of inflammation and auto-aggressive processes in IBD. © 2012 Springer-Verlag Italia.

References Powered by Scopus

Get full text

This article is free to access.

Get full text

Cited by Powered by Scopus

This article is free to access.

This article is free to access.

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Malíčková, K., Ďuricová, D., Bortlík, M., Janatková, I., Zima, T., & Lukáš, M. (2013). Phosphatidylserine-dependent anti-prothrombin antibodies (aPS/PT) in infliximab-treated patients with inflammatory bowel diseases. Autoimmunity Highlights, 4(1), 27–32. https://doi.org/10.1007/s13317-012-0045-0

Readers over time

‘13‘14‘15‘16‘18‘19‘20‘21‘22‘2302468

Readers' Seniority

Tooltip

Researcher 3

43%

Professor / Associate Prof. 2

29%

PhD / Post grad / Masters / Doc 2

29%

Readers' Discipline

Tooltip

Agricultural and Biological Sciences 2

33%

Medicine and Dentistry 2

33%

Biochemistry, Genetics and Molecular Bi... 1

17%

Pharmacology, Toxicology and Pharmaceut... 1

17%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 6

Save time finding and organizing research with Mendeley

Sign up for free
0